Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 0.4% in the afternoon session after the company shared ...

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced ...

Myriad Genetics has seen a subtle but notable uptick in its fair value estimate, with analysts revising the figure from $7.95 to $8.29. This slight increase comes as experts reassess the company's ...

Myriad Genetics has broadened the scope of its MyRisk Hereditary Cancer Test for germline testing, adding genes.

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled ...

Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Myriad Genetics (NASDAQ:MYGN) presented its third quarter 2025 earnings results on November 3, 2025, reporting revenue of $205.7 million, representing a 4% year-over-year decline.

Good day, and thank you for standing by. Welcome to the Myriad Genetics' Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being ...

Myriad Genetics Inc (MYGN) reported its Q3 2025 earnings, with revenue surpassing expectations at $206 million, slightly above the forecast of $204.97 million. Despite a 4% year-over-year revenue ...